Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 894 results for "mylan"

Mylan's Blogger Recruits May Have Been Buttered Up to Help Pass Bills
Fortune

The EpiPen's public flogging: A congressional committee condem...

Mylan NL CEO Heather Bresch holds EpiPens during a House Oversight and Government Reform Committee hearing on the Rising Price of EpiPens at the Capitol, September 21, 2016. (Credit: Reuters/Yuri Gripas) Drug manufacturer Mylan's CEO Heather ... Salon, 1 day ago
[x]  

1,143 images for mylan

Mideast Time, 8 hours ago
American Banking News, 23 hours ago
WCVB.com, 2 days ago
WCVB.com, 2 days ago
American Banking News, 23 hours ago
Money Morning, 1 day ago
Business Times Singapore, 2 days ago
CNBC, 1 day ago
MSN News US, 2 days ago
Japan Times, 2 days ago
American Banking News

Deutsche Tweaking Its Mylan View Following CEO's Congressional Testimony

Deutsche Bank trimmed its estimates and target price on Mylan NV (NASDAQ: MYL ) shares following CEO Heather Bresch's Congressional testimony over the price hike of EpiPen allergy shots. Mylan raised the price of EpiPen, which accounts for 40 ...
 Benzinga.com1 day ago Argus Reiterates $55.00 Price Target for Mylan Inc. (MYL)  American Banking News23 hours ago Mylan Inc. (MYL) Given a $55.00 Price Target at Argus  Ticker Report1 day ago Mylan Inc. (MYL) PT Set at $55.00 by Argus  American Banking News1 day ago
[x]  

Where Did All That EpiPen Money Go?

Everyone has opinions about the Mylan (NASDAQ: MYL ) (let's call it a) situation. The "reason" given by CEO Heather Bresch for the skyrocketing costs of EpiPens involves the way the medical reimbursement game is played. Rebates are demanded, ...
 Seeking Alpha1 day ago Mylan Investors Should Be Asking Where (And Who) Robert Coury Is  Benzinga.com4 days ago
Benzinga.com

USA Today On EpiPen Saga: Calling It 'Controversial' Is Far From Haphazard

Mylan NV (NASDAQ: MYL )'s EpiPen controversy, in which the company may have been unjustified in raising the cost of its life saving device over the years, is far from over. Even though Mylan's CEO Heather Bresch sat in front of a U.S. House ...
 Benzinga.com1 day ago

Biotech Forum Daily Digest: Can Biotech Broach Resistance Levels? Worst Now Over For Mylan? Spotlight Feature On Bellicum Pharmaceuticals

"Politics, n. Strife of interests masquerading as a contest of principles." - Ambrose Bierce What a difference a few months makes. Late in June the biotech sector was again near the bottom of a trading range that has existed throughout 2016 ...
 Seeking Alpha1 day ago

Ask the right questions even when there are no easy answers

Case in point yesterdays hearing before the House Oversight and Government Reform Committee on price hikes for Mylan's life-saving product, EpiPen. The price hikes deserve careful examination but Mylan CEO Heather Bresch does not deserve to take ...
 The Hill1 day ago House committee holds hearing on rising price of drug-injecting device  AHA News1 day ago

Mylan CEO: Reformulating EpiPen to Have Longer Shelf Life

Mylan CEO Heather Bresch said that the company is reformulating EpiPen so that it will have a longer shelf life. She told the House Oversight Committee that reformulation should extend the drug out to 24 months from the current 18 months.
 Bloomberg1 day ago
Huffington Post

Here's What Pissed-Off Congressmen Said to Mylan's CEO

Mylan MYL CEO Heather Bresch responded to questions from the House Oversight Committee Wednesday as Congress continues its probe into the company's price hikes on EpiPens. Despite their usual partisan gridlock, members of Congress united to ...
 Yahoo! Finance2 days ago Mylan CEO: EpiPen $608 Price Was Fair  Northern Territory News2 days ago Rep. Duckworth Questions Mylan CEO on EpiPen Sales to Schools  Tasmania Mercury2 days ago Members Of Congress Rip Into Mylan CEO  Huffington Post2 days ago
[x]  
Investor's Business Daily

Even Free-Market Republicans Say Mylan Went Too Far On EpiPen

When push came to shove, Mylan ( MYL ) couldn't find any friends among Republicans, even though they said they wished they could defend the drugmaker. At a congressional hearing in Washington Wednesday, GOP lawmakerswho described themselves as ...
 Investor's Business Daily2 days ago Free-Market Republicans Bash Mylan, Say EpiPen Went Too Far  Bloomberg2 days ago Free-Market Republicans Turn on Mylan, Say EpiPen Went Too Far  Yahoo! Finance2 days ago
WCVB.com

Lawmakers say EpiPen made Mylan execs 'filthy rich'

Cost of life-saving EpiPens up over 400% Mylan CEO Heather Bresch insisted Wednesday that the outrage swirling around her company's decision to dramatically hike the cost of its EpiPen has been overblown. Bresch said the company's profit on ...
 CNN Money2 days ago Lawmakers say EpiPen hikes made Mylan executives 'filthy rich'  WCVB.com2 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - mylan
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less